Top-News
Werbung

Attraktive Knock-Outs auf Pfizer Inc.

Typ Hebel Bid / Ask WKN
Call
4,9 5,30 € / 5,38 €
SU98AP
Call
9,9 0,26 € / 0,27 €
SW9YK3
Typ Hebel Bid / Ask WKN
Put
4,9 0,53 € / 0,54 €
SW4E53
Put
10,2 2,56 € / 2,64 €
SU74DS
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Pfizer Inc.
Pharmazeutika USA

Pfizer Inc. News

Aktie
WKN:  852009 ISIN:  US7170811035 US-Symbol:  PFE
26,26 €
-0,16 €
-0,61%
14:52:29 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
5,65 Mrd.
Marktkapitalisierung *
149,26 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
S&P 500
IR-Website
zur Website
*Stand: 10.01.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,11: VM8ATU

Unternehmensmeldungen

01.06.24 - Businesswire
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS ® (brentuximab vedotin) in combination with ...
31.05.24 - Businesswire
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
Pfizer Inc. (NYSE: PFE) today announced longer-​term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-​generation ALK inhibitor, available ...
06.05.24 - Businesswire
Pfizer Announces New Chief Strategy and Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a ...
01.05.24 - Businesswire
Pfizer Reports First-Quarter 2024 Results
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted (3) diluted EPS guidance while maintaining all other components of its 2024 ...
29.04.24 - Businesswire
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO ® ) Annual ...
26.04.24 - Businesswire
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-​dzkt) for the treatment of adults with ...
24.04.24 - Businesswire
Pfizer Declares Second-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-​quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to ...
22.04.24 - Businesswire
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Pfizer Inc . (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO ® (aztreonam-​avibactam) for the treatment of ...
11.04.24 - Businesswire
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-​only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on ...
09.04.24 - Businesswire
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial ( NCT05842967 ) MONeT (RSV I M munizati ...
20.03.24 - Businesswire
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, ...
07.06.22 - DGAP
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
Hardman & Co Research Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry 07-Jun-2022 / 07:30 GMT/BST Hardman & Co ...
17.02.21 - DGAP
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder
DGAP-News: Imcyse SA / Key word(s): Financing Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder 17.02.2021 / 14:00 ...
03.02.21 - DGAP
Imcyse scelle avec Pfizer un accord de collaboration de recherche et de licence portant sur sa technologie Imotope(TM) dans le domaine de la polyarthrite rhumatoïde
Imcyse SA / Mot-clé(s) : Autres Imcyse scelle avec Pfizer un accord de collaboration de recherche et de licence portant sur sa technologie Imotope(TM) dans le domaine de la ...
03.02.21 - DGAP
Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid Arthritis
DGAP-News: Imcyse SA / Key word(s): Agreement Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid ...
24.09.20 - DGAP
Medizintechnikunternehmen avateramedical N.V. beruft Ian Read, ehemaliger Chairman und CEO von Pfizer, in den Aufsichtsrat
DGAP-News: avateramedical GmbH / Schlagwort(e): Personalie Medizintechnikunternehmen avateramedical N.V. beruft Ian Read, ehemaliger Chairman und CEO von Pfizer, in den ...
05.08.19 - DGAP
Form 8.3 - The Vanguard Group, Inc.: BCA Marketplace plc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: BCA Marketplace plc 05-Aug-2019 / 14:20 GMT/BST Dissemination of a Regulatory Announcement, transmitted by ...
02.05.19 - DGAP
Empower Clinics Inc.: Nach Mega-Übernahme - Größter Cannabis Klinikbetreiber der USA entsteht! Kursanstieg voraus!
DGAP-​Media / 02.05.2019 / 08:42
09.04.19 - DGAP
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
Hardman & Co Research Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales 09-Apr-2019 / 16:10 GMT/BST
02.04.19 - DGAP
Empower Clinics Inc.: Überraschender Einstieg von Agraflora bei Empower - deutliche Kursteigerung bei Empower heute möglich!
DGAP-​Media / 02.04.2019 / 11:45

Newssuche

Videos

newspaper
29.05.24 +24,01%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »